SHARE

August 16, 2022

The Inflation Reduction Act of 2022: Key Health Care Provisions

You've Reached Your
Free Article Limit This Month
Register for free to get unlimited access to all Law.com OnPractice content.
Register Now

On Aug. 7, 2022, the U.S. Senate passed the Inflation Reduction Act of 2022 (IRA), which the House of Representatives passed five days later, on Aug. 12. President Biden is expected to sign the sweeping piece of legislation into law Aug. 16. The IRA includes provisions aimed at addressing a range of issues - including energy and climate, tax, and health care.

The health care provisions include significant reforms that will directly impact consumers and health care stakeholders. This GT Alert summarizes the IRA's key health care provisions.

Prescription Drug Pricing Reform

Lowering Prices Through Drug Price Negotiation

One of the most widely publicized provisions of the bill authorizes the Centers for Medicare & Medicaid Services (CMS), to negotiate drug prices for the Medicare program. The "Drug Price Negotiation Program" will require CMS to negotiate maximum prices for brand name drugs that do not have generic equivalents and that account for the greatest Medicare spending. The program will begin in 2026 and include 10 negotiation-eligible drugs, then will increase to 15 negotiation-eligible drugs in 2027 and 2028, then 20 drugs in 2029 and each year following.

The secretary of the Department of Health and Human Services (HHS) will be tasked with entering into agreements with the drug manufacturers to determine the maximum fair price to individuals, pharmacies, hospitals, physicians, and other providers of services who administer or dispense the drugs. The legislation includes a specific negotiation process and timeline, and also outlines factors to be considered in setting fair market value, including research and development costs.

Prescription Drug Inflation Rebates

In addition to authorizing CMS to directly negotiate prices for applicable drugs, the bill also requires drug manufacturers to issue rebates to CMS for brand-name drugs without generic equivalents under Medicare that cost $100 or more per year per individual with prices increasing faster than inflation. Drugs will be evaluated every calendar year on or after Jan. 1, 2023, through a reporting requirement for Medicare drugs. CMS will determine the inflation-adjusted payment amount with a reduction or waiver for shortages and severe supply chain disruption. Manufacturers that fail to comply will be subject to civil monetary penalties.

Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries

The bill includes a benefit structure redesign beginning in 2026 that modifies the reinsurance payment amount to 20% of the allowable reinsurance costs attributable to that portion of gross covered prescription drug costs incurred for applicable drugs; for non-applicable drugs, the amount is 40% of such allowable reinsurance costs attributable.

The bill also establishes a manufacturer discount program where the secretary of HHS is authorized to enter into agreements with manufactures participating in Medicare Part D. Under such agreements, manufacturers will provide discounted prices for applicable drugs dispensed to applicable beneficiaries on or after Jan. 1, 2025. Agreements must be for a minimum of 12 months and include data and compliance requirements.

A manufacturer that fails to provide discounted prices for applicable drugs under a covered agreement will be subject to a civil monetary penalty for each failure.

Continued Delay of Implementation of Prescription Drug Rebate Rule

The IRA extend the moratorium on implementation of the final rule that relates to eliminating the anti-kickback statute Safe Harbor Protection for Prescription Drug Rebates, issued by the Office of the Inspector General on Nov. 30, 2020. The moratorium is extended until Jan. 1, 2032.

Additional Items

The IRA includes required coverage for adult vaccines recommended by the Advisory Committee on Immunization Practices under Medicare Part D. It also includes expanding eligibility for low-income subsidies under Part D and improving access to adult vaccines under Medicaid and the Children's Health Insurance Program.

While there was significant debate related to capping out-of-pocket insulin costs for all consumers, the final law imposes a $35 monthly cap on out-of-pocket spending on insulin for Medicare beneficiaries only. The cap does not apply to private payers.

There is also a limitation on monthly coinsurance and adjustments to supplier payments under Medicare Part B for insulin furnished through durable medical equipment. Additionally, there is a safe harbor for high-deductible health plans that do not impose a deductible for insulin-related products. Under the safe harbor, such a plan may still be treated as a high-deductible health plan.

Affordable Care Act Subsidies

Finally, the bill extends the value of Affordable Care Act subsidies to certain consumers who receive subsidies for health care insurance through the marketplace through 2025.

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From Greenberg Traurig

California AG Announces Investigation of Mobile Apps' CCPA Compliance

By Gretchen A. Ramos Greenberg Traurig January 31 , 2023

On Jan. 27, 2023, the California Attorney General announced his office is investigating and sending letters to businesses in the retail, travel, and food industries with popular mobile apps that allegedly are not in compliance with the California Consumer Privacy Act (CCPA) by failing to offer a consumer opt-out mechanism for sales, or honor rights requests submitted via authorized agents.

E2 Law Podcast: Episode 20 | Empire Environmental - Review of New York's Cap-and-Invest Program to Reduce Emissions and Achieve Climate Goals

By Steven C. Russo Greenberg Traurig January 27 , 2023

In this episode of Greenberg Traurig's E2 Podcast, attorneys Steven Russo, Zackary Knaub, and Jane McLaughlin discuss New York State’s cap-and-invest program to limit greenhouse gas emissions and share revenue with New Yorkers from disadvantaged communities to help cover utility bills, transportation costs, and decarbonization.

5 Trends to Watch: 2023 Data Privacy & Cybersecurity

By Gretchen A. Ramos Greenberg Traurig January 26 , 2023

While ransomware attacks have been on the rise since 2020, a recent trend has emerged where threat actors are bypassing ransomware malware and encryption tactics and going straight to data theft.

More From Health Care Law

This Week in 340B: January 17 - 23, 2023

By Emily Jane Cook McDermott Will & Emery January 26 , 2023

This weekly series provides brief summaries to help you stay in the know on how 340B cases are developing across the country.

Trends to Watch: 2023 Pharmaceutical, Medical Device & Health Care Litigation

By Sara K. Thompson Greenberg Traurig January 25 , 2023

The Judicial Panel on Multidistrict Litigation (JPML) received fewer requests to create new MDLs over the past year (granting only a handful), yet the few that were created are likely to be significantly larger than average MDLs of years past.

Trending in Telehealth: January 17 - 23, 2023

By Dale C. Van Demark McDermott Will & Emery January 24 , 2023

Trending in Telehealth is a new weekly series from the McDermott Digital Health team where we highlight state legislative and regulatory developments that impact the healthcare providers, telehealth and digital health companies, pharmacists, and technology companies that deliver and facilitate the delivery of virtual care.

Featured Stories
Closeclose
Search
Menu

Working...